SynAct missed primary endpoint in EXPAND study. Funding need makes RESOLVE readout next material milestone. New TP of SEK 17 (170), downgrade to HOLD (Buy).
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Author:
ABGSC Healthcare Research | Gonzalo Artiach
Pages:
15
SynAct missed primary endpoint in EXPAND study. Funding need makes RESOLVE readout next material milestone. New TP of SEK 17 (170), downgrade to HOLD (Buy).
